Home › Trials › NCT03930953

Evaluating CC-99282 for relapsed or refractory non-Hodgkin lymphomas

A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).

Phase1; Phase2 Interventional Celgene · NCT03930953

This study is testing a new treatment called CC-99282 for people with non-Hodgkin lymphomas that haven't responded to previous therapies to see how safe and effective it is.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Enrollment438 (estimated)
Ages18 Years and up
SexAll
SponsorCelgene Industry-sponsored
Locations92 sites (Scottsdale, Arizona and 91 other locations)
Trial IDNCT03930953 on ClinicalTrials.gov

What this trial studies

This study aims to assess the safety, tolerability, and preliminary efficacy of CC-99282, both as a standalone treatment and in combination with other anti-lymphoma agents, for patients with relapsed or refractory non-Hodgkin's lymphomas. Participants must have previously failed at least two lines of therapy or be ineligible for further standard treatments. The study includes a dose escalation phase to determine the maximum tolerated dose of CC-99282 and a dose expansion phase to further evaluate its efficacy. Additionally, the study will investigate the effects of food on the pharmacokinetics and safety of CC-99282.

Who should consider this trial

Good fit: Ideal candidates are individuals with relapsed or refractory non-Hodgkin's lymphoma who have failed multiple prior therapies.

Not a fit: Patients with a life expectancy of two months or less or those with significant cardiac issues may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with difficult-to-treat non-Hodgkin lymphomas.

How similar studies have performed: Other studies have shown promise with similar approaches in treating non-Hodgkin lymphomas, suggesting potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

Exclusion Criteria:

* Life expectancy ≤ 2 months
* Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter
* Is on chronic systemic immunosuppressive therapy or corticosteroids or has clinically significant graft-versus-host disease (GVHD)
* Impaired cardiac function or clinically significant cardiac disease

Other protocol-defined inclusion/exclusion criteria apply

Where this trial is running

Scottsdale, Arizona and 91 other locations

+42 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Lymphoma, Non-HodgkinNon-Hodgkin LymphomasSafetyEfficacyCC-99282RituximabRelapsedRefractory
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.